Sort
39,280 grants matching “leukemia”
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies
$630,540Smita Bhatia · Beckman Research Institute/City Of Hope · R01 · FY2011 · CA
Total Synthesis of Anti-Cancer Natural Products
$630,466Phil S Baran · Scripps Research Institute, The · R01 · FY2009 · CA
Total Synthesis of Anti-Cancer Natural Products
$630,466Phil S Baran · Scripps Research Institute, The · R01 · FY2010 · CA
Developing novel therapies to improve blood stem cell transplantation outcomes
$630,428Ramiro Garzon · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL
Targeting retroviral and virus-like particles for gene and protein delivery
$630,341Monica J Roth · Rbhs-Robert Wood Johnson Medical School · R35 · FY2020 · GM
Targeting retroviral and virus-like particles for gene and protein delivery
$630,341Monica J Roth · Rbhs-Robert Wood Johnson Medical School · R35 · FY2021 · GM
Targeting retroviral and virus-like particles for gene and protein delivery
$630,341Monica J Roth · Rbhs-Robert Wood Johnson Medical School · R35 · FY2018 · GM
Targeting retroviral and virus-like particles for gene and protein delivery
$630,341Monica J Roth · Rbhs-Robert Wood Johnson Medical School · R35 · FY2019 · GM
Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies
$630,238Richard J Simpson · University Of Arizona · R01 · FY2025 · CA
Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children
$630,217Catherine Metayer · University Of California Berkeley · R01 · FY2023 · ES
Molecular Epidemiology of NHL and CLL
$629,749James R Cerhan · Mayo Clinic Rochester · R01 · FY2008 · CA
Proteolytic disregulation of the S326C mutant OGG1 DNA repair enzyme
$629,545Michele K Evans · National Institute On Aging · ZIA · FY2009 · AG
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
$629,467Renata Pasqualini · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Oogenic JNK in gonadotoxic chemotherapy-induced primary ovarian insufficiency
$629,384Shuo Xiao · Rutgers Biomedical And Health Sciences · R01 · FY2025 · HD
Germline and Somatic Genomic Studies in CLL Minorities
$629,224Susan L Slager · Mayo Clinic Rochester · R01 · FY2024 · CA
Research and Development of Effective Therapies for Patients with Rare Tumors
$629,166Brigitte Widemann · Division Of Clinical Sciences - Nci · ZIA · FY2020 · CA
Phenotypic variability within isogenic population of lymphocytes
$629,064Grãgoire Altan-Bonnet · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
$628,719Jin Wang · Baylor College Of Medicine · R01 · FY2023 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
$628,719Jin Wang · Baylor College Of Medicine · R01 · FY2022 · CA
Developmental Funds
$628,683Raphael E. Pollock · Ohio State University · P30 · FY2025 · CA
Clinical Development of Immunotherapies for Rare Hematologic Maligancies
$628,666Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
O-Glycosylation of Epidermal Growth Factor-like Motifs
$628,633Robert S. Haltiwanger · State University New York Stony Brook · R01 · FY2014 · GM
Genetic and molecular basis for SRSF2 mutations in myelodysplasia
$628,575Robert K Bradley · Fred Hutchinson Cancer Research Center · R01 · FY2018 · HL
TCR engineered T cell therapies for hematologic malignancies
$628,503Kazusa Ishii · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Roles of Endogenous Retroviruses in Cancer and Auto-immune Diseases
$628,378Leonard Evans · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI